Neuromuscular blocking agents (NMBAs) can be classified into three main groups based on their duration of action: short-acting, intermediate-acting, and long-acting agents. The choice of agent depends on the specific surgical or clinical needs, as well as patient factors, such as organ function and the desired length of muscle paralysis. The duration of action directly influences the depth and length of muscle relaxation, impacting both intraoperative management and postoperative recovery.
Short-Acting Neuromuscular Blocking Agents
Short-acting NMBAs, like succinylcholine and mivacurium, are typically used in situations where only a brief period of muscle paralysis is required. These agents are ideal for procedures that demand quick and temporary paralysis, such as in rapid sequence induction (RSI) for endotracheal intubation.
Succinylcholine is the most commonly used short-acting NMBA. It is preferred in emergencies or situations where rapid muscle relaxation is critical, particularly when securing an airway is the top priority. As a depolarizing agent, it works by mimicking acetylcholine (ACh) and causing initial muscle fasciculations, followed by paralysis. While highly effective for short periods, it has significant side effects, including potential for hyperkalemia and malignant hyperthermia, and is therefore used cautiously, especially in patients with specific risk factors.
Mivacurium, a non-depolarizing NMBA, is another option when short-term muscle relaxation is needed. It is less commonly used in modern practice due to the availability of more versatile agents. However, its use is beneficial in cases where short-acting paralysis is required without the hyperkalemia or malignant hyperthermia risk associated with succinylcholine. Like succinylcholine, mivacurium is hydrolyzed by plasma cholinesterase, so its effect is also prolonged in pseudocholinesterase deficiency, and a rapid large dose can release histamine.
Intermediate-Acting Neuromuscular Blocking Agents
Intermediate-acting NMBAs are widely favored in clinical practice due to their balance between effective muscle relaxation and controlled recovery. Agents like rocuronium, vecuronium, and atracurium provide sufficient paralysis for most surgical procedures without lingering effects that may delay recovery.
Rocuronium is a non-depolarizing agent known for its rapid onset, making it a popular choice when a longer-lasting alternative to succinylcholine is needed, such as in surgeries requiring ongoing muscle relaxation. Rocuronium is often paired with sugammadex, a reversal agent that can quickly neutralize its effects, providing flexibility in recovery timing.
Vecuronium is another intermediate-acting NMBA with a similar profile to rocuronium but slightly slower onset. It is commonly used for longer surgeries, and its effects can be reversed with traditional agents like neostigmine. Vecuronium offers predictable muscle relaxation with fewer cardiovascular effects, making it a reliable choice in many surgical scenarios. Vecuronium, like Rocuronium, can be easily reversed with Sugammadex.
Atracurium, belonging to the benzylisoquinolinium class, is metabolized independently of liver or kidney function, making it a preferred choice for patients with compromised organ function. Cisatracurium, a stereoisomer of atracurium, offers similar benefits with a lower risk of side effects like histamine release, which may cause hypotension or tachycardia in certain patients.
Long-Acting Neuromuscular Blocking Agents
Long-acting NMBAs are used in surgeries or clinical situations where extended muscle paralysis is necessary. These agents maintain prolonged muscle relaxation, which can be beneficial in lengthy or complex surgical procedures. However, they are less commonly used today due to their extended recovery period and potential for residual neuromuscular blockade (rNMB), which can lead to postoperative respiratory complications.
Pancuronium is the primary long-acting agent in use, particularly for procedures requiring sustained paralysis. Its prolonged effects ensure uninterrupted muscle relaxation but may require careful management during recovery to avoid delayed reversal of the blockade. Pancuronium can also cause tachycardia and hypertension, which are important considerations in patients with cardiovascular conditions.
Long-acting agents like tubocurarine and gallamine have largely been replaced by shorter-acting options due to their unfavorable side effects, including significant histamine release and prolonged recovery.
| Duration group | Agents | Clinical role and cautions |
|---|---|---|
| Short-acting | Succinylcholine, mivacurium | Brief paralysis, such as rapid sequence induction for endotracheal intubation; succinylcholine carries the potential for hyperkalemia and malignant hyperthermia, while mivacurium avoids those effects but is less commonly used in modern practice |
| Intermediate-acting | Rocuronium, vecuronium, atracurium | Sufficient paralysis for most surgical procedures without lingering effects that delay recovery; rocuronium and vecuronium are readily reversed with sugammadex, and atracurium is metabolized independently of liver or kidney function. Cisatracurium, a stereoisomer of atracurium, offers similar benefits with a lower risk of histamine release |
| Long-acting | Pancuronium | Sustained paralysis for lengthy or complex procedures, at the cost of extended recovery, potential residual neuromuscular blockade, and vagolytic tachycardia and hypertension |
| Long-acting, largely replaced | Tubocurarine, gallamine | Superseded by shorter-acting options because of significant histamine release and prolonged recovery |
